Skip to content
lifestyle.getpetsavvy.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
argenx SE
argenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc.
August 6, 2026
argenx announces Extraordinary General Meeting of Shareholders on September 17, 2026
August 3, 2026
argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class anti-CD122 Antibody, FB102, to its Immunology Pipeline
July 27, 2026
argenx Reports Half Year 2026 Financial Results and Provides Second Quarter Business Update
July 23, 2026
argenx to Report Half Year 2026 Financial Results and Second Quarter Business Update on July 23, 2026
July 16, 2026
argenx to Host Autoimmune Myositis R&D Webinar
June 23, 2026
argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
May 8, 2026
argenx Reports First Quarter 2026 Financial Results and Provides Business Update
May 7, 2026
argenx to Present at BofA Securities 2026 Health Care Conference
May 6, 2026
argenx Announces Results of Annual General Meeting and Board of Directors’ Appointment of Karen Massey as Chief Executive Officer
May 6, 2026
1
2
Next Page
→